ChemSpider 2D Image | dapagliflozin (S)-propylene glycol hydrate | C24H35ClO9

dapagliflozin (S)-propylene glycol hydrate

  • Molecular FormulaC24H35ClO9
  • Average mass502.982 Da
  • Monoisotopic mass502.196960 Da
  • ChemSpider ID28529466

  • defined stereocentres - 5 of 5 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

dapagliflozin (S)-propylene glycol hydrate
(2S)-1,2-Propandiol --(1S)-1,5-anhydro-1-[4-chlor-3-(4-ethoxybenzyl)phenyl]-D-glucitolhydrat (1:1:1) [German] [ACD/IUPAC Name]
(2S)-1,2-Propanediol - (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol hydrate (1:1:1) [ACD/IUPAC Name]
(2S)-1,2-Propanediol - (1S)-1,5-anhydro-1-[4-chloro-3-(4-éthoxybenzyl)phényl]-D-glucitol, hydrate (1:1:1) [French] [ACD/IUPAC Name]
1,2-Propanediol, (2S)-, compd. with D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, hydrate (1:1:1) [ACD/Index Name]
887K2391VH
960404-48-2 [RN]
BMS-512148-05
DAPAGLIFLOZIN PROPANEDIOL
dapagliflozin propanediol monohydrate
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Chemical Class:

      A hydrate that consists of dapagliflozin compounded with (<stereo>S</stereo>)-propylene glycol and hydrate in a (1:1:1) ratio. Used to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. ChEBI CHEBI:85079
      A hydrate that consists of dapagliflozin compounded with (S)-propylene glycol and hydrate in a (1:1:1) ratio. Used to improve glycemic control, along with diet and exercise, in adults with type 2 diab etes. ChEBI CHEBI:85079
      A hydrate that consists of dapagliflozin compounded with (S)-propylene glycol and hydrate in a (1:1:1) ratio. Used to improve glycemic control, along with diet and exercise, in adults; with type 2 di abetes. ChEBI https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:85079

    • Bio Activity:

      Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment of type 2 diabetes mellitus (T2DM). MedChem Express http://www.medchemexpress.com/canagliflozin.html, HY-10450A
      Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment of type 2 diabetes mellitus (T2DM). ;IC50 value:;Target: SGLT2Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. From Wikipedia. MedChem Express HY-10450A
      Membrane Tranporter/Ion Channel MedChem Express HY-10450A
      Membrane Tranporter/Ion Channel; MedChem Express HY-10450A
      SGLT MedChem Express HY-10450A

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement